应用MRI弥散成像表观弥散系数监测肝转移瘤化疗疗效研究*

doi:10.3969/j.issn.1672-5069.2012.05.0016

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (5): 421-423.doi: 10.3969/j.issn.1672-5069.2012.05.0016

应用MRI弥散成像表观弥散系数监测肝转移瘤化疗疗效研究^*

许永华, 徐敬慈, 杨利霞, 潘晓东, 彭薇

200031上海市徐汇区中心医院/中国科学院上海临床中心医学影像科

收稿日期:2012-01-26 出版日期:2012-10-10 发布日期:2017-03-09
作者简介:许永华男,46岁,主任医师,教授, 博士研究生导师。主要从事影像学诊断和肿瘤介入放射治疗研究。E-mail: howardyonghua@gmail.com
基金资助:
江苏大学临床医学科技发展基金资助（编号：JLY20080092）

Application of apparent diffusion coefficient for predicting response of hepatic metastases to chemotherapy

Xu Yonghua, Xu Jingci, Yang Lixia, at al.

Department of Medical Imaging,Xuhui Central Hospital Affiliated to Shanghai Medical Center,China Academy of Sciences,Shanghai 200031

Received:2012-01-26 Online:2012-10-10 Published:2017-03-09

摘要/Abstract

摘要： 目的评估应用磁共振弥散加权成像表观弥散系数（ADC）预测和早期监测肝转移瘤化疗疗效的可行性。方法选择43例原发肿瘤为胃肠道、乳腺或其他部位的肝转移瘤患者,在化疗前和化疗后2~3周常规检查弥散加权成像并获得相应的ADC值。采用RECIST作为评价肝转移肿瘤化疗疗效的标准。结果在43例肝转移瘤68个病灶中,30个病灶对化疗有效,38个病灶对化疗无效,其治疗前平均ADC值分别为1.22±0.39×10^-3 mm²/s 和 1.54±0.55×10^-3 mm²/s（P=0.008）;在治疗后2周,化疗有效组ADC值升至1.43×10^-3 mm²/s（P=0.005）,而化疗无效则降至1.23×10^-3 mm²/s（P=0.13）;以ADC值=1.50×10^-3 mm²/s为治疗有效或无效的临界点,其判断疗效的阳性预测值为94%,阴性预测值为92%,准确率为93%。结论磁共振弥散加权成像ADC可作为预测肝转移瘤化疗疗效的影像学指标。

关键词: 肝肿瘤, 化学治疗, 磁共振成像, 表观弥散系数

Abstract: Objective To investigate the feasibility of apparent diffusion coefficients（ADC） in diffusion weighted MR imaging in predicting response to chemotherapy in patients with hepatic metastatic tumors. Methods Forty-three consecutive patients with hepatic metastases from gastric and colorectal cancer,breast cancer and other tumors underwent MRI diffusion-weighted imaging（DWI） sequences before and 2 to 3 weeks following chemotherapy for assessing the ADC value of lesions. RECIST was utilized to evaluate the efficacy of the chemotherapy. Results A total of 68 lesions in the 43 patients were observed,and the sizes of hepatic metastases decreased in 30 ones（the respond group） and increased or did not change in 38 ones （the non-respond group） after chemotherapy. The mean ADC values of lesions were 1.22±0.39×10^-3 mm²/s in the respond group and 1.54±0.55×10^-3 mm²/s in the non-respond group（P=0.008）,respectively;After treatment,the ADC values increased to 1.43×10^-3 mm²/s（P=0.005） in the responders,whereas they decreased to 1.23×10^-3 mm²/s（P=0.13） in the non-responders;We supposed ADC equal to 1.50×10^-3 mm²/s as a threshold value for responders and non-responders,the positive predictive value,negative predictive value and accuracy were 94%,92% and 93%,respectively. Conclusion ADC value of diffusion weighted MR imaging was potential to be an imaging marker for predicting and assessing early chemotherapeutic responses of hepatic metastases.

Key words: Liver neoplasms, Chemotherapy, MR imaging, Apparent diffusion coefficient

许永华, 徐敬慈, 杨利霞, 潘晓东, 彭薇. 应用MRI弥散成像表观弥散系数监测肝转移瘤化疗疗效研究^*[J]. 实用肝脏病杂志, 2012, 15(5): 421-423.

Xu Yonghua, Xu Jingci, Yang Lixia, at al.. Application of apparent diffusion coefficient for predicting response of hepatic metastases to chemotherapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(5): 421-423.

参考文献

[1] van Persi JN,Meerten EL,Gelderblom H,et al. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol,2010,2（6）:1456-1467.
[2] Jordan BF,Runquist M,Raghunand N,et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia,2005,7（5）:475-485.
[3] Cui Y,Zhang XP,Sun YS,et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology,2008,248（3）:894-900.
[4] Buijs M,Kamel IR,Vossen JA,et al. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol,2007,18（8）:957-963.
[5] Chen CY,Li CW,Kuo YT,et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants initial experience. Radiology,2006,239（2）:448-456.
[6] 陈智伟,廖美琳. RECIST标准在肿瘤治疗疗效评价中的应用. 中国肿瘤,2004,13（10）:616-618.
[7] Aboagye EO,Bhujwalla ZM,He Q,et al. Evaluation of lactate as a 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat Res,1998,150（1）:38-42.
[8] Rizzo S,Summers P,Raimondi S,et al. Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy. Radiol Med,2011,116（5）:766-780.
[9] Deng J,Rhee TK,Sato KT et al. In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla. Invest Radiol,2006,41（4）:410-414.
[10] 束敏,杜联军,丁晓毅,等. MR扩散加权成像在骨肉瘤新辅助化疗疗效评估中的价值. 中华放射学杂志,2009,43（6）：571-574.
[11] Koh DM,Scurr E,Collins D,et al. Predicting response of colorectal hepatic metastasis:value of pretreatment apparent diffusion coefficients. AJR,2007,188（4）:1001-1008.
[12] Dzik-Jurasz A, Domenig C, George M et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet,2002,360（9329）:307-308.
[13] El Kady RM,Choudhary AK,Tappouni R,et al. Accuracy of apparent diffusion coefficient value measurement on PACS work station:A comparative analysis. AJR,2011,196（3）:W280-284.
[14] Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol,2003,45（3）:169-184.

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[3]	叶显俊, 何年安, 隋秀芳, 刘力. 二维超声和超声造影检查肝脏上皮样血管内皮瘤表现特征分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 904-907.
[4]	金良红, 李兴杰, 关红博, 麻少辉. 双能量CT碘定量结合动态对比增强MRI评估肝硬化患者肝脏血流动力学和肝功能临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 712-715.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	李林昌. 泡型肝包虫病多脏器侵犯MRI表现^*[J]. 实用肝脏病杂志, 2019, 22(4): 585-588.
[7]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[8]	李鹏, 刘小丽, 喻奇志. MRI对肝孤立性坏死结节诊断及鉴别诊断价值研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 129-132.
[9]	任宏伟, 高志华. 静息态fMRI技术观察肝性脑病患者双侧苍白球与全脑网络连接的改变研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 920-923.
[10]	马茜, 张帅, 苗红, 赵新光, 田诗云. 钆塞酸二钠增强MR与增强CT诊断肝脏局灶性病变效能对比研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 951-954.
[11]	鲁雪红, 张源, 刘文亚. 多排螺旋CT三期增强与3.0T MR多期动态增强扫描诊断肝细胞癌的价值分析^*[J]. 实用肝脏病杂志, 2018, 21(5): 749-752.
[12]	李飞飞, 金彪, 王永杰, 邹明, 沈加林. 磁共振扩散峰度成像检测原发性肝癌及其周围组织参数分析[J]. 实用肝脏病杂志, 2018, 21(5): 809-810.
[13]	汪登斌. 肝脏疾病影像学诊断技术新进展[J]. 实用肝脏病杂志, 2018, 21(4): 489-492.
[14]	王文涛, 饶圣祥. 肝脏局灶性实性病变的影像学诊断思路[J]. 实用肝脏病杂志, 2018, 21(4): 493-495.
[15]	杨云飞. 全腹部薄层冠状面单次激发快速自旋回波序列MRI检查诊断小儿胆管疾病的价值分析[J]. 实用肝脏病杂志, 2018, 21(4): 617-620.

应用MRI弥散成像表观弥散系数监测肝转移瘤化疗疗效研究^*

Application of apparent diffusion coefficient for predicting response of hepatic metastases to chemotherapy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价